Gタンパク質共役受容体（GPCR）市場の2030年までの予測： 製品タイプ別、アッセイタイプ別、用途別、地域別の世界分析

Stratistics MRCによると、世界のGタンパク質共役受容体（GPCR）市場は2023年に37億米ドルを占め、予測期間中にCAGR7.1％で成長し、2030年には59億8,000万米ドルに達すると予測されています。

Gタンパク質共役受容体（GPCR）として知られる多様な膜受容体群は、7（パス）トランス膜受容体とも呼ばれます。これらは細胞膜に存在し、外部の化学物質と相互作用し、細胞内分子にシグナルを伝達する役割を担っています。GPCRは細胞表面受容体であり、ペプチド、タンパク質、光エネルギー、脂質、糖として伝達されるメッセージの受信箱として機能します。これらの受容体は、炎症性疾患、代謝障害、心疾患、がん、単発性疾患など、幅広い疾患の治療に頻繁に用いられています。

米国心臓協会の2021年版ジャーナルによると、米国では2035年までに1億3,000万人以上の成人が何らかの心臓病を患うと予想されています。

慢性疾患の増加

慢性疾患の増加は、Gタンパク質共役受容体（GPCR）市場の強力な促進要因となっています。GPCRは多くの生理的プロセスの制御に極めて重要な役割を果たしており、貴重な創薬ターゲットとなっています。糖尿病、心血管疾患、神経変性疾患などの慢性疾患による世界の負担の増大に伴い、GPCRを標的とした医薬介入に対する需要が高まっています。研究者は革新的な治療法を求めてGPCRを探索しており、これが製薬業界の研究開発を刺激しています。

Gタンパク質共役受容体（GPCR）細胞株の高価格

Gタンパク質共役受容体（GPCR）細胞株の高価格は、GPCR市場の大きな抑制要因となっています。これらの細胞株取得に伴う多額のコストは、小規模な研究機関やバイオテクノロジー新興企業にとっては法外なものであり、GPCR関連の研究や医薬品開発に従事する能力を制限します。このような価格設定の障壁は、イノベーションを阻害し、競合を減少させ、GPCRの理解と標的化における科学の進歩を妨げ、新薬の発見を遅らせる可能性があります。

創薬におけるGPCRの世界的普及

創薬におけるGタンパク質共役受容体（GPCR）の広範な採用は、市場にとって大きなチャンスです。GPCRは様々な生理的プロセスの制御に関与する多様な薬剤標的クラス別であり、医薬品研究にとって極めて重要です。その多様性と、がん、神経疾患、代謝性疾患を含む多くの疾患への関与により、関心が高まっています。創薬研究がますます世界化する中、GPCRは革新的な医薬品開発の有望な手段となります。新規治療薬のターゲットとしてGPCRが採用されることで、研究開発の取り組みが強化され、新規薬剤への道が開かれるとともに、GPCR市場が世界規模で大きく成長する可能性が高まっています。

GPCRシグナル伝達系の複雑さ

GPCRとして知られる細胞表面受容体ファミリーは、多くの異なるタイプの受容体を含み、複雑なシグナル伝達系を持っています。GPCRがさまざまなリガンドや下流のシグナル伝達カスケードとどのように相互作用するのかを理解するのは難しく、新薬の発見や既存薬の開発をより困難にしています。このように複雑であるため、新薬候補の有効性を予測することは難しく、予期せぬ悪影響のリスクも高くなります。さらに、多くの調査、最先端技術、共同研究が必要となり、費用も時間もかかります。これらすべての要素が市場の成長を抑制すると予想されます。

COVID-19の影響：

Gタンパク質共役受容体（GPCR）市場は、COVID-19の大流行によって様々な面で大きな影響を受けています。研究所の閉鎖やパンデミック関連の研究にリソースを再配分した結果、創薬に不可欠なGPCRの研究が停滞しました。その一方で、GPCR創薬のための計算科学的手法やバーチャルスクリーニング手法の導入が急がれました。GPCRが免疫反応に果たす役割やウイルス感染症の治療に役立つ可能性から、市場ではGPCRを標的とした治療薬の需要が増加しました。全体として、パンデミックはGPCR市場に影響を及ぼし、イノベーションを促進し、デジタル手法への移行によってイノベーションを阻害しました。

予測期間中、cAMPファンクショナルアッセイセグメントが最大となる見込み

cAMPファンクショナルアッセイ分野は、予測期間中に最大の市場シェアを記録すると予想されています。cAMPアッセイは、GPCRの活性化やシグナル伝達経路の研究に広く利用されており、潜在的な薬剤候補の同定に不可欠です。cAMPアッセイによって、研究者はリガンドに対するGPCRの反応を評価することができ、薬剤の有効性と安全性に関する貴重な知見を得ることができます。GPCRを標的とした薬剤の需要が高まるにつれ、cAMPアッセイが注目されるようになり、市場での優位性を高めています。

予測期間中にCAGRが最も高くなるがん研究分野

がん研究分野は、がんの進行においてGPCRが果たす極めて重要な役割により、予測期間中に最も高い成長率を示しています。研究により、GPCRが腫瘍の成長、血管新生、転移に関与していることが明らかになっており、がん治療の魅力的な標的となっています。さらに、個別化医療が重視されるようになり、GPCRを標的とした抗がん剤が開発されたことも、新興国市場の成長を後押ししています。がんにおけるGPCRシグナル伝達の解明が進んだことで、革新的な治療法が急増し、GPCR関連研究ツールの需要が高まっています。

最大のシェアを占める地域：

予測期間中、経済的にも技術的にも先進国である米国、カナダ、メキシコに牽引され、北米が最大の市場シェアを占めると予測されています。米国がん協会によると、2022年には米国だけで190万人の新規がん患者が発生し、60万9,360人ががん関連で死亡すると予測されています。同様に、カナダがん統計2021は、カナダ人のおよそ5人に2人が一生の間にがんの診断を受け、4人に1人がこの病気で亡くなることを明らかにしました。北米の市場成長をさらに後押ししているのは、慢性疾患、特に心血管疾患とがんの負担であり、これが最先端の療法と治療に対する需要を高めています。

CAGRが最も高い地域：

アジア太平洋地域は、NB Health Laboratory、HD Biosciences Co.Ltd.、Sosei Heptaresのような数多くの若い企業が存在するため、予測期間中に最も高い成長が見込まれます。地域的な成長は、企業が市場での存在感を高めるためにとる数々の取り組みに影響されます。さらに、地域的な拡大は、中国、インド、その他の経済圏の拡大する人口における生活習慣病の有病率の増加と、受容体による治療の必要性によっても促進されます。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の競合関係

第5章 世界のGタンパク質共役受容体（GPCR）市場：製品別

• 細胞培養試薬
• 細胞株
• 検出キット
• リガンド

第6章 世界のGタンパク質共役受容体（GPCR）市場：アッセイタイプ別

• cAMP機能アッセイ
• カルシウム機能アッセイ
• 内部移行アッセイ
• 放射性リガンド結合およびGTPγS機能アッセイ
• 人身売買アッセイ
• B-アレスチン機能アッセイ
• その他のアッセイタイプ

第7章 世界のGタンパク質共役受容体（GPCR）市場：用途別

• がんの研究
• 心臓血管の研究
• 中枢神経系（CNS）の研究
• 炎症の研究
• 代謝の研究
• 呼吸器の研究
• その他の用途

第8章 世界のGタンパク質共役受容体（GPCR）市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Abcam PLC
• Accure Pharma
• Actelion
• Addex Pharmaceuticals Ltd
• Arena Pharmaceuticals, Inc.
• BD（Becton, Dickinson and Company）
• BioInvenu, Inc.
• Cisbio Bioassays
• Corning Incorporated
• Enzo Life Sciences, Inc.
• Eurofins DiscoverX
• HD Biosciences Co., Ltd
• Merck Group
• Molecular Devices, LLC.
• PerkinElmer Inc.
• Promega Corporation
• Qiagen
• Thermo Fisher Scientific
• WuXi AppTec
• Confo Therapeutics

List of Tables

• Table 1 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 4 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 5 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 6 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 7 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 8 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 9 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 10 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 11 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 12 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 13 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 14 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 15 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 16 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 17 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 18 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 19 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 21 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 22 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 23 Global G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 24 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Country (2021-2030) ($MN)
• Table 25 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 26 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 27 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 28 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 29 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 30 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 31 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 32 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 33 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 34 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 35 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 36 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 37 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 38 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 39 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 40 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 41 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 42 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 44 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 45 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 46 North America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 47 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Country (2021-2030) ($MN)
• Table 48 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 49 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 50 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 51 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 52 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 53 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 54 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 55 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 56 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 57 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 58 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 59 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 60 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 61 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 62 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 63 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 64 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 65 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 67 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 68 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 69 Europe G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 70 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Country (2021-2030) ($MN)
• Table 71 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 72 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 73 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 74 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 75 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 76 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 77 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 78 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 79 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 80 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 81 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 82 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 83 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 84 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 85 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 86 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 87 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 88 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 90 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 91 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 92 Asia Pacific G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 93 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Country (2021-2030) ($MN)
• Table 94 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 95 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 96 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 97 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 98 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 99 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 100 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 101 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 102 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 103 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 104 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 105 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 106 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 107 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 108 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 109 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 110 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 111 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 113 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 114 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 115 South America G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 116 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Country (2021-2030) ($MN)
• Table 117 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Product (2021-2030) ($MN)
• Table 118 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Culture Reagents (2021-2030) ($MN)
• Table 119 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cell Lines (2021-2030) ($MN)
• Table 120 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Detection Kits (2021-2030) ($MN)
• Table 121 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Ligands (2021-2030) ($MN)
• Table 122 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Assay Type (2021-2030) ($MN)
• Table 123 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By cAMP Functional Assays (2021-2030) ($MN)
• Table 124 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Calcium Functional Assays (2021-2030) ($MN)
• Table 125 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Internalization Assays (2021-2030) ($MN)
• Table 126 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Radioligand Binding and GTPγS Functional Assays (2021-2030) ($MN)
• Table 127 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Trafficking Assays (2021-2030) ($MN)
• Table 128 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By B-Arrestin Functional Assays (2021-2030) ($MN)
• Table 129 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Assay Types (2021-2030) ($MN)
• Table 130 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Application (2021-2030) ($MN)
• Table 131 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cancer Research (2021-2030) ($MN)
• Table 132 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Cardiovascular Research (2021-2030) ($MN)
• Table 133 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Central Nervous System (CNS) Research (2021-2030) ($MN)
• Table 134 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Inflammation Research (2021-2030) ($MN)
• Table 136 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Metabolic Research (2021-2030) ($MN)
• Table 137 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Respiratory Research (2021-2030) ($MN)
• Table 138 Middle East & Africa G-Protein Coupled Receptors (GPCRs) Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global G-Protein Coupled Receptors (GPCRs) Market is accounted for $3.70 billion in 2023 and is expected to reach $5.98 billion by 2030 growing at a CAGR of 7.1% during the forecast period. The diverse group of membrane receptors known as G-Protein Coupled Receptors (GPCRs), also referred to as seven-(pass)-trans membrane receptors. These can be found in the cell membrane and are in charge of interacting with external chemicals and relaying signals to intracellular molecules. GPCRs are cell surface receptors that function as an inbox for messages delivered as peptides, proteins, light energy, lipids, and sugars. These receptors are frequently employed in the management of a wide range of illnesses, including inflammatory disorders, metabolic disturbances, cardiac disorders, cancer, and monogenic disorders.

According to the American Heart Association's 2021 Journal, more than 130 million adults in the United States are expected to have some type of heart disease by 2035.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The increasing prevalence of chronic diseases serves as a robust driver in the G-Protein Coupled Receptors (GPCRs) market. GPCRs play a pivotal role in regulating numerous physiological processes, making them valuable drug targets. With a growing global burden of chronic conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders, the demand for pharmaceutical interventions that target GPCRs is on the rise. Researchers are exploring GPCRs for innovative therapeutic solutions, which has stimulated research and development in the pharmaceutical industry.

Restraint:

High cost of G-protein coupled receptors (GPCRs) cell lines

The high price of G-Protein Coupled Receptors (GPCRs) cell lines represents a significant restraint in the GPCR market. The substantial cost associated with acquiring these cell lines can be prohibitive for smaller research institutions and biotech startups, limiting their ability to engage in GPCR-related research and drug development. This pricing barrier can stifle innovation, reduce competition, and impede scientific progress in understanding and targeting GPCRs, potentially slowing down the discovery of new pharmaceuticals.

Opportunity:

Adoption of GPCRs in drug discovery across the world

The widespread adoption of G-Protein Coupled Receptors (GPCRs) in drug discovery represents a significant opportunity for the market. GPCRs are a diverse class of drug targets involved in regulating various physiological processes, making them crucial for pharmaceutical research. Their versatility and involvement in numerous diseases, including cancer, neurological disorders, and metabolic conditions, have led to increased interest. As drug discovery efforts become increasingly globalized, GPCRs offer a promising avenue for innovative drug development. This adoption of GPCRs as targets for new therapeutics enhances research and development initiatives, paving the way for novel medications, and underscores the substantial growth potential in the GPCR market on a global scale.

Threat:

Complexity of the GPCR signalling system

The family of cell surface receptors known as GPCRs includes many different types of receptors and has complex signaling systems. It can be difficult to comprehend how they interact with different ligands and downstream signaling cascades, which makes it more difficult to find new drugs and develop existing ones. Because of this complexity, it is harder to predict a drug candidate's effectiveness, and there is a higher risk of unanticipated negative effects. Additionally, a lot of research, cutting-edge technology, and collaboration are needed, which are expensive and time-consuming. All of these elements are expected to restrain market growth.

COVID-19 Impact:

The G-Protein Coupled Receptors (GPCR) market has been significantly impacted by the COVID-19 pandemic in a number of ways. Lab closures and resource redistribution towards pandemic-related studies resulted in a slowdown in the study of GPCRs, which are essential for drug discovery. On the other hand, it has hastened the adoption of computational and virtual screening techniques for GPCR drug development. Due to the role that GPCRs play in immune responses and the potential they provide for treating viral infections, the market saw an increase in demand for GPCR-targeted therapies. Overall, the pandemic affected the GPCR market by fostering innovation and stifling it with a move toward digital methods.

The cAMP functional assays segment is expected to be the largest during the forecast period

The cAMP functional assays segment is anticipated to register the largest market share in the anticipated timeframe. This is due to its critical role in drug discovery and understanding cellular signaling. cAMP assays are widely utilized for studying GPCR activation and signaling pathways, making them integral to identifying potential drug candidates. They enable researchers to assess GPCR responses to ligands, providing valuable insights into drug efficacy and safety. With the rising demand for GPCR-targeted drugs, cAMP assays have gained prominence, driving their dominance in the market.

The cancer research segment is expected to have the highest CAGR during the forecast period

The cancer research segment is experiencing the highest growth rate during the forecast period due to the pivotal role GPCRs play in cancer progression. Research has revealed GPCRs' involvement in tumor growth, angiogenesis, and metastasis, making them attractive targets for cancer therapy. Additionally, the market's growth is fueled by the increased emphasis on personalized medicine and the development of GPCR-targeted cancer drugs. Advances in understanding GPCR signaling in cancer have led to a surge in innovative therapies and a growing demand for GPCR-related research tools, positioning this segment for substantial expansion in the near future.

Region with largest share:

During the forecast period, North America is anticipated to witness largest market share, led by the economically and technologically developed nations of the United States, Canada, and Mexico. According to the American Cancer Society, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths in the United States alone in 2022. In a similar vein, the Canadian Cancer Statistics 2021 revealed that roughly 2 in 5 Canadians will receive a cancer diagnosis during their lifetime and that 1 in 4 will pass away from the disease. Further bolstering market growth in North America is the burden of chronic diseases, particularly in cardiovascular and cancer applications, which is raising demand for cutting-edge therapies and treatments.

Region with highest CAGR:

Asia-Pacific is expected to experience the highest growth during the forecast period due to the presence of a number of young businesses like NB Health Laboratory, HD Biosciences Co., Ltd., and Sosei Heptares. Regional growth is influenced by the number of initiatives companies take to enhance their market presence. Furthermore, regional expansion is also fueled by the growing prevalence of lifestyle disorders among the expanding populations of China, India, and other economies, as well as the need to treat them with receptors.

Key players in the market:

Some of the key players in G-Protein Coupled Receptors (GPCRs) market include: Abcam PLC, Accure Pharma, Actelion, Addex Pharmaceuticals Ltd, Arena Pharmaceuticals, Inc., BD (Becton, Dickinson and Company), BioInvenu, Inc., Cisbio Bioassays, Corning Incorporated, Enzo Life Sciences, Inc., Eurofins DiscoverX, HD Biosciences Co., Ltd, Merck Group, Molecular Devices, LLC., PerkinElmer Inc., Promega Corporation, Qiagen, Thermo Fisher Scientific WuXi AppTec and Confo Therapeutics.

Key Developments:

In March 2023, Confo Therapeutics, a leader in targeting G-Protein Coupled Receptors (GPCRs) (GPCRs), this week announced an agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed CNS target. Confo will receive upfront and milestone payments totaling $183 million and tiered royalties on sales from any resulting products.

In December 2022, Sosei Group Corporation announced its partnership with Eli Lilly and Company, a global biopharmaceutical firm. The collaboration aims to facilitate drug discovery for novel G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases, including the development and commercialization of small molecules with therapeutic potential.

In April 2022, Ono Pharmaceutical Co., Ltd. signed a new collaboration agreement with Domain Therapeutics and Universite de Montreal to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) (GPCRs) in a metabolic disease area.

Products Covered:

• Cell Culture Reagents
• Cell Lines
• Detection Kits
• Ligands

Assay Types Covered:

• cAMP Functional Assays
• Calcium Functional Assays
• Internalization Assays
• Radioligand Binding and GTPγS Functional Assays
• Trafficking Assays
• B-Arrestin Functional Assays
• Other Assay Types

Applications Covered:

• Cancer Research
• Cardiovascular Research
• Central Nervous System (CNS) Research
• Inflammation Research
• Metabolic Research
• Respiratory Research
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global G-Protein Coupled Receptors (GPCRs) Market, By Product

• 5.1 Introduction
• 5.2 Cell Culture Reagents
• 5.3 Cell Lines
• 5.4 Detection Kits
• 5.5 Ligands

6 Global G-Protein Coupled Receptors (GPCRs) Market, By Assay Type

• 6.1 Introduction
• 6.2 cAMP Functional Assays
• 6.3 Calcium Functional Assays
• 6.4 Internalization Assays
• 6.5 Radioligand Binding and GTPγS Functional Assays
• 6.6 Trafficking Assays
• 6.7 B-Arrestin Functional Assays
• 6.8 Other Assay Types

7 Global G-Protein Coupled Receptors (GPCRs) Market, By Application

• 7.1 Introduction
• 7.2 Cancer Research
• 7.3 Cardiovascular Research
• 7.4 Central Nervous System (CNS) Research
• 7.5 Inflammation Research
• 7.6 Metabolic Research
• 7.7 Respiratory Research
• 7.8 Other Applications

8 Global G-Protein Coupled Receptors (GPCRs) Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abcam PLC
• 10.2 Accure Pharma
• 10.3 Actelion
• 10.4 Addex Pharmaceuticals Ltd
• 10.5 Arena Pharmaceuticals, Inc.
• 10.6 BD (Becton, Dickinson and Company)
• 10.7 BioInvenu, Inc.
• 10.8 Cisbio Bioassays
• 10.9 Corning Incorporated
• 10.10 Enzo Life Sciences, Inc.
• 10.11 Eurofins DiscoverX
• 10.12 HD Biosciences Co., Ltd
• 10.13 Merck Group
• 10.14 Molecular Devices, LLC.
• 10.15 PerkinElmer Inc.
• 10.16 Promega Corporation
• 10.17 Qiagen
• 10.18 Thermo Fisher Scientific
• 10.19 WuXi AppTec
• 10.20 Confo Therapeutics